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Abstract
The availability of high-throughput molecular profiling techniques has provided
more accurate and informative data for regular clinical studies. Nevertheless,
complex computational workflows are required to interpret these data. Over the
past years, the data volume has been growing explosively, requiring robust
human data management to organise and integrate the data efficiently. For this
reason, we set up an ELIXIR implementation study, together with the
Translational research IT (TraIT) programme, to design a data ecosystem that
is able to link raw and interpreted data. In this project, the data from the TraIT
Cell Line Use Case (TraIT-CLUC) are used as a test case for this system.
Within this ecosystem, we use the European Genome-phenome Archive (EGA)
to store raw molecular profiling data; tranSMART to collect interpreted
molecular profiling data and clinical data for corresponding samples; and
Galaxy to store, run and manage the computational workflows. We can
integrate these data by linking their repositories systematically. To showcase
our design, we have structured the TraIT-CLUC data, which contain a variety of
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our design, we have structured the TraIT-CLUC data, which contain a variety of
molecular profiling data types, for storage in both tranSMART and EGA. The
metadata provided allows referencing between tranSMART and EGA, fulfilling
the cycle of data submission and discovery; we have also designed a data flow
from EGA to Galaxy, enabling reanalysis of the raw data in Galaxy. In this way,
users can select patient cohorts in tranSMART, trace them back to the raw data
and perform (re)analysis in Galaxy. Our conclusion is that the majority of
metadata does not necessarily need to be stored (redundantly) in both
databases, but that instead FAIR persistent identifiers should be available for
well-defined data ontology levels: study, data access committee, physical
sample, data sample and raw data file. This approach will pave the way for the
stable linkage and reuse of data.
 This article is included in the   gateway.ELIXIR
 This article is included in the   gateway.Galaxy
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Introduction
Translational research, or translational medicine, sets out to 
translate novel biological insights into clinical diagnostic tools, 
medicine, procedures, policies and education1,2. Recent develop-
ments in high-throughput profiling techniques like next genera-
tion sequencing3, followed by third generation sequencing4 and 
the earlier techniques like tandem mass spectrometry5 and 
microarrays6, have revolutionised translational research. Raw 
data generated by these techniques require extensive computa-
tion by bioinformatics workflows7, which transform raw data 
into interpreted data. The impressive number of observables per 
sample (e.g. genes, transcripts, exon positions, or peptide frag-
ments) indicates that we need more samples to enhance the sta-
tistical power in filtering relevant biological events; moreover, it 
is still expensive to generate new molecular profiling data for 
research8. Subsequently, there is an increasing need to be able 
to reuse patient-derived high-throughput molecular profiling 
data from existing studies. The clinical and pathological informa-
tion of such samples should also be stored to allow reanalysis. 
Additionally, all of these data are privacy sensitive, and hence 
require careful storage and controlled access. Here, we describe 
how those needs can be implemented into a well-designed data 
management ecosystem for archiving, linking and reusing data to 
facilitate the data-driven translational research on a large scale.
We consider two potential usage scenarios: 1) the process associ-
ated with generating the data; and 2) the process associated with 
reusing previously generated data. Note that the starting point in 
the two processes are different: in the former, the user starts by 
storing and computationally processing the raw data from the 
high-throughput experiments (green lines in Figure 1:A), whereas 
the latter process naturally starts from exploring, analysing or 
querying the interpreted data (orange lines in Figure 1:A).
Many previous initiatives have focused on the implementation 
of infrastructures for processing and storing previously gener-
ated data9–11, but few focus on the scenario of reusing the data. 
Several consortia currently provide data infrastructures aimed to 
enable life science research12–15. Moreover, various initiatives have 
pushed the idea to make scientific results and data more openly 
accessible16–19. In light of this, a joint effort between ELIXIR and 
TraIT has been established to set up an implementation study 
with the aim of designing an ecosystem connecting existing 
data systems to enable effective reuse of the data. ELIXIR20 is 
Figure 1. The usage scenario considered in the implementation study. A: The process for data generation (green lines) is different 
from that for data reuse (orange lines). B–D: Intended scenario of reusing data for translational research: first, the samples of interest can 
be discovered by exploring the clinical and interpreted data in tranSMART (v16.1); note that it is essential to present enough metadata for 
effective exploration (B); next, the raw data in EGA can be traced back from the interpreted data in tranSMART (C); finally, workflows can be 
re-applied to the raw data in Galaxy (D).
Page 4 of 14
F1000Research 2017, 6:1488 Last updated: 14 NOV 2017
an intergovernmental organisation which builds on existing data 
resources and services within Europe, enhancing European-wide 
biological research. Translational research IT (TraIT) is estab-
lished as a large public-private partnership to develop, implement 
and maintain a long-lasting IT infrastructure for translational 
research in the Netherlands. In this work, we describe the 
setup, results and recommendations of the EGA-TraIT ELIXIR 
implementation study.
Several resources and databases have been dedicated to store, 
query, explore, process and analyse human data. In this study, we 
aim to connect the European Genome-phenome Archive (EGA)21, 
tranSMART10,22,23, and Galaxy24,25. Currently, tranSMART (v16.1) 
and Galaxy are deployed by TraIT, while the EGA infrastructure 
is supported by CRG, EBI and ELIXIR. tranSMART is an open 
source framework and cloud platform for integrating molecular 
plus clinical data and exploring these; therefore tranSMART is a 
natural starting point for reusing data by making data findable. 
Galaxy is an open source bioinformatics workflow management 
system7,25, in which workflows can be run intuitively to analyse 
the biomolecular profiling raw data by users without program-
ming expertise. The European Genome-phenome Archive (EGA) 
is a longterm data repository for molecular profiling and phe-
notypic data, where data are stored, managed, referenced and 
distributed with strict access control. As of June 2017, more than 
1160 studies are available at EGA, with over 8000 data access 
accounts. It thus has become a highly used archive for raw human 
translational research data, helping to improve data accessibility.
The intended usage scenario of the implementation study is the 
reproduction and reanalysis of archived data, and can be outlined 
as follows: a life science researcher is exploring the interpreted 
and clinical data in tranSMART (Figure 1B) to find a few specific 
samples of interest; they then can retrieve the identifiers for 
these samples in EGA, and thus retrieve the raw data from EGA 
(Figure 1C), and (re)apply computational workflows made 
available through Galaxy (Figure 1D).
Here we report the full outcome of this implementation study; 
previously, we described the connection between Galaxy and 
EGA26. In this paper, we show a proof of concept that demon-
strates the feasibility of linking data resources for reusing archived 
data, with the help of the TraIT Cell Line Use Case (TraIT-CLUC) 
data. Nevertheless, the dramatic differences in data models 
between data resources, like EGA and tranSMART (Figure 2), 
have posed a major challenge for the interoperability of link-
ing data. We finalise this work with a recommendation on how to 
transform the proof of concept into a mature solution. We show 
how to bridge the distinct data models of the different data 
sources by using persistent identifiers (PID), and explain how this 
befits the FAIR16 use of human data and computational workflows 
in translational research: findable, accessible, interoperable and 
reusable.
Results and discussion
Data ecosystem design
We designed a data ecosystem in this implementation study 
connecting part of the TraIT infrastructure with EGA, as 
shown in Figure 3; in this figure, the blue arrows show the links 
implemented in this study. Note that we emphasise the proc-
ess for reusing data here, starting from the interpreted data in 
tranSMART, linking back to the raw data in EGA that can be 
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Figure 2. Metadata mapping between EGA and tranSMART. The data model of EGA is dramatically different from that of tranSMART 
(v16.1) due to the deviating purposes and designs of the systems. Furthermore, in both systems, there is an intrinsic flexibility in defining the 
data model. EGA uses the SRA (sequence read archive) data model for NGS data with the addition of array data from array and genotyping 
experiments. EGA also exports all sample objects to BioSamples, ensuring each sample has a BioSample ID. tranSMART focuses on the 
clinical information and interpreted biomolecular profiling data. The data model has a patient-centered, but flexible structure which also 
shows some design choices due to the underlying relational database. Terminology is not the same between tranSMART and EGA - partially 
due to the SRA data model employed at EGA, such that an experiment describes the library and platform used for sequencing experiments 
only. In tranSMART, a wider range of experiments can be described. DAC is a data access committee. The sample level, which is lacking in 
tranSMART v16.1, will be supported from v17.1.
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Figure 3. A designed data ecosystem based on TraIT: interpreted data together with clinical data can be explored in tranSMART, 
subsequently tracked back to the raw data in EGA, and finally, raw data in EGA can be imported to Galaxy, where workflows can be 
applied to the raw data. The blue arrows in this figure depict the connections implemented as a proof of concept by the current work.
imported within Galaxy. Galaxy can subsequently be used to rerun 
the workflows over the raw data or perform novel analyses.
ELIXIR implementation proof of concept
The TraIT Cell Line Use Case (TraIT-CLUC) raw data, which are 
non-privacy sensitive, were made public in EGA. Via the EGA 
help desk, anyone can access them for testing and developing 
workflows.
With the TraIT-CLUC data, we showcase an implementation of data 
model mapping between tranSMART and EGA (Figure 4), which 
enables the envisioned data reuse process. Users in tranSMART 
can: trace back all the interpreted data in one study to all the raw 
data file IDs by EGA study ID, which is in the metadata of the study 
in tranSMART - (1) in Figure 4.
1.    trace back all the interpreted data under one specific experi-
ment type to the raw data file IDs by the EGA Dataset ID. 
The EGA Dataset ID can be found in the metadata of node 
"EGA files" and its parent node (e.g."RNA expression") in 
the tree view - (2) and (3) in Figure 4.
2.    trace back one piece of specific interpreted data under one 
specific experiment type to the raw data files by EGA file 
IDs, which are the leaf nodes of the node ‘EGA files’ in the 
tree view and rendered as columns in ‘Grid View’ - (4) in 
Figure 4.
Once the users in tranSMART retrieve EGA file IDs, they can 
directly import the raw data files into a Galaxy instance with 
the Galaxy tool “EGA download streamer”26. Subsequently, the 
workflow in Galaxy can be applied to these data for reproduction 
or new analysis.
Implemented improvements to EGA
During the upload of the TraIT-CLUC data, there had been extensive 
communication and feedback between the TraIT and EGA team. 
This has resulted in an improved data uploading pipeline. EGA has 
implemented a FUSE layer, which allows all files received from 
EGA via the downloader to be stored in an encrypted format on 
the remote filesystem. This also allows processes to natively access 
these files and decrypt them automatically as they are accessed, 
removing the need for a separate specific decryption step and hence 
the storage of unencrypted files on a remote filesystem and the 
associated security concerns. This implementation is now being 
extended to allow remote file transfer to remote clouds. 
In order to improve the findability of data stored in EGA, a draft 
API has been implemented which allows objects to be queried 
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Figure 4. An implementation in tranSMART (v16.1) of metadata mapping between tranSMART and EGA. (1): The study level mapping; 
if one hovers over the node ‘TraIT-Cell-line’ study node, one can see the EGA study identifier. (2) and (3): Metadata of node “EGA files” and 
its parent node (e.g.“RNA expression”) in the tree view contains one EGA dataset ID that those EGA file IDs (i.e. the leaf nodes of “EGA 
files”) belong to (dataset in EGA is similar to series in GEO). (4): After dragging the node “EGA files” in the tree view to ‘Grid View’, raw data 
files with EGA File IDs are rendered in a few columns in ‘Grid View’, where each row stands for a mapping from the interpreted data to its 
corresponding raw data files. Each subnode (not leaf node) of node “EGA files” in the tree view corresponds to a column in ‘Grid View’. 
Therefore, the interpreted data in tranSMART can be traced back to the corresponding raw data archived in EGA, either via the corresponding 
files or via the entire dataset.
and filtered, with the response in JSON format. The objects to 
return are specified, followed by the object and ID to filter by. For 
example, the following query returns the datasets associated with 
study EGAS00001001476: https://test.ega-archive.org/metadata/
v2/datasets?queryBy=study&queryId= EGAS00001001476. It is 
also possible to retrieve the BioSample and EGA IDs of the samples 
associated with the study using the following query: https://test.
ega-archive.org/metadata/v2/samples? queryBy=study&queryId=E
GAS00001001476&limit=0.
The current work has improved the level of FAIRness of the 
infrastructure in several ways. The findability (F), even though in 
this case of a controlled access database, has been improved by 
generating a link back to the raw data. The accessibility (A), in 
this case with controlled access, has also been improved by 
allowing data import using EGA identifiers in Galaxy to access 
the raw data, making it thereby reusable (R). The main challenge 
in the implementation study is the interoperability (I), i.e., the 
data model mapping between EGA and tranSMART, which are 
unsurprisingly different from each other (Figure 2). Below we 
outline recommendations to further improve the FAIRness of 
this ecosystem for privacy sensitive human data.
Recommendation to implement a proof of concept
In this ELIXIR EGA-TraIT implementation study, we showed a 
proof of concept for linking EGA, tranSMART and Galaxy, effec-
tively providing an ecosystem for translational high-throughput 
biomolecular profiling data. However, the current implementa-
tion of metadata mapping between tranSMART and EGA will 
become more cumbersome when one item of interpreted data 
corresponds to multiple raw data files, which leads to multiple 
columns in the “grid view” of tranSMART. In this situation, to 
allow the further development of technical links, user-friendly 
interfaces, better provenance of computational methods and a 
more structural solution is required. Below we will outline our 
recommendations, which will ensure interoperability between 
different elements of these ecosystems, and thus allow the 
development of user-friendly work processes.
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Recommendations to move from a proof of concept to a 
mature solution
The ELIXIR implementation study aimed to show a proof of 
concept for a functioning ecosystem, in which data could be reused 
by life science researchers. In order to make a user-friendly, and 
more mature ecosystem, some further improvements need to be 
made: 
1.    The current implementation of the Galaxy EGA down-
load streamer means that all users of one Galaxy instance 
have to share one user credential to access EGA data. 
Currently, Galaxy does not support password input type. 
This means that any password will be inadvertently 
recorded in the Galaxy history, and thereby compromise 
the security of EGA credentials; the current implemen-
tation is an ad hoc solution to this problem. A generic 
solution in Galaxy should be offered to securely inte-
grate with the third-party authentication27; this would also 
enable secure personal access to nonpublic databases 
besides EGA.
2.    From a user perspective, error messages from the Galaxy 
EGA download streamer should be easily interpretable. 
Currently, it is difficult to obtain associated metadata 
on the EGA file identifiers, making it difficult to implement 
helpful error messages. For example, it may be unclear to 
the user why there is no access to a certain file, and who 
should be approached if access is needed. This could be 
addressed if metadata on EGA identifiers would be exposed 
in a more generic, machine readable format, preferably in 
RDF.
3.    Likewise, human readable metadata associated with EGA 
identifiers, such as the file identifier, should be exposed, so 
that researchers can find their way to the correct datasets, 
studies and data access committees covering the files of 
interest. Currently, if a life science researcher finds an EGA 
file ID in tranSMART, and does not have EGA access yet, 
it is very difficult to find out to which EGA dataset or study 
it belongs.
4.    For life science researchers, a more direct reference from 
tranSMART to suitable computational workflows would 
be highly desirable. In terms of provenance, a reference to 
the workflow that produced the data would be sufficient; 
however, for reusing data by the life science researchers, it 
would be helpful if a direct link to a workflow on a Galaxy 
instance were available. This issue has for example been 
addressed in the myFAIR Analysis project.
5.    Many bioinformaticians running production workflows 
for generating interpreted data do not, in fact, use 
Galaxy. An important reason for this is that Galaxy does 
not always give enough control over the data usage and 
job scheduling to allow computationally expensive work-
flows to be run efficiently on HPC systems. Moreover, a 
bioinformatician — who wants to make a Galaxy workflow 
available as provenance over the dataset and increase 
reusability of the data — needs to make additional efforts 
to port the workflow to Galaxy. Any steps that make this 
porting easier, will in the longer term greatly serve the 
provenance of interpreted data.
Recommendations to systematically link data resources for 
human data
Currently, data models used to capture clinical cohorts vary 
strongly between different data resources (Figure 2). However, 
aligning these data models, or mapping them via metadata, would 
only partially resolve the problem for the following reasons:
1) Translational research is a rapidly changing field; study and 
cohort structures rapidly evolve to reflect the fast advances in data 
science and high-throughput molecular profiling techniques.
2) Different elements within any such ecosystem can have multi-
farious purposes and can aim to serve a different market of users.
3) Metadata is essential for good data stewardship16; nevertheless, 
the purposes of data resources may indicate which metadata is 
required; moreover, metadata may need to be corrected or updated 
over time (see for example the fate of the TCGA barcodes).
4) Making huge amounts of (overlapping) metadata a requirement 
in each data resource will increase the barrier for data submission 
to any resource.
In this context, we make a different suggestion that ensures inter-
operability between these systems without the need to align their 
full relational structures: globally resolvable and unique persist-
ent identifiers (PID)28 should be generated for well-defined entities 
in all data resources, and should be used to link the data between 
data resources (Figure 4). Furthermore, we suggest that following 
ontology concepts need to be assigned such persistent identifiers: 
Study, Data Access Committee (DAC), Physical Sample, Data 
Sample, and Data File (Figure 5).
We suggest the following requirements should hold for each of 
these persistent identifiers: 
1.    A single authority should be responsible for minting the 
persistent identifier, which also entails a scheme to define 
what the string looks like, and for standardising minimally 
required metadata applied for the identifier within the 
consortium.
2.    Any data resource offering these PIDs should make sure 
the relations between the PID entities are resolvable by 
querying their database, for those PIDs included in the 
resource. For example, if EGA contains a File PID, we 
should be able to ask for the associated DAC PID.
Such persistent identifiers would be very similar to the recently 
introduced ORCID ID for researchers. Several data resources, as 
held by publishers, libraries and funding agencies, are including 
this in their systems, which obviates the need for a homogeneous 
relational structure or perfectly overlapping metadata. The linkage 
of one ORCID ID with multiple DOIs makes the publications and 
academic activities of one researcher easily traceable, creating a 
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fully workable researcher-centered ecosystem with a wide range of 
data resources and applications.
Note that it is not necessary for all types of PIDs to be governed by 
a single authority. Currently, EGA has two types of PIDs listed at 
identifiers.org: the EGA study and EGA Dataset. All EGA samples 
also have a BioSamples PID, which links to the publicly accessi-
ble attributes of the sample. To fully adhere to the above criteria, 
EGA would need to ensure that the controlled-access attributes are 
available via an EGA PID, along with EGA PIDs for Experiment, 
Analysis, Run, and Array. The additional PID types required may 
also be given out by other authorities; distributed governance of 
PID types would not diminish their usefulness.
With our recommendations, this implementation study specific data 
ecosystem will further progress towards FAIR guiding principles. 
If the associated metadata of these PIDs are made available as 
linked data, the findability (F) could easily be ensured by meta-
data exposing systems such as bioschemas30 or wikidata31; in this 
way, users could easily access the metadata and PIDs in Wikipe-
dia via search engines. A file PID or Data Sample PID should be 
associated with at least one DAC PID, ensuring that high-through-
put biomolecular profiling data can be authorised and accessed 
(A). The implementation of PIDs in linking metadata specifi-
cally achieves the interoperability (I) between different systems. 
Raw data in EGA can be reused in Galaxy for further analy-
sis in our data ecosystem and the rich metadata will help users 
Figure 5. Suggested usage of persistent identifiers to link concepts between the data models of EGA and tranSMART. The data model 
of EGA differs much from that of tranSMART; for example, a tranSMART experiment has a different conceptual meaning compared to the 
EGA ‘experiment’, which is one of the four ‘processing’ objects at EGA (experiment, run, analysis, and array). A few well-defined entities with 
persistent identifiers (PIDs) are essential to achieving the interoperability between the systems. From this implementation study, Study PID, 
File PID and DAC PID are thought to be essential for systematic mapping for a stable ecosystem allowing to reuse data. Moreover, from a 
TraIT perspective, stable identifier types that describe the physical sample (Physical Sample PID) and the raw data associated with such a 
sample (Data Sample PID) are desirable. For the first concept, the BioSample definition could be used, for the second concept, it is clear 
that there is a need for a well-defined aggregate identifier above the file level that covers all raw output data from a single experiment on 
a single sample. Ongoing studies aim to generate a well-defined level for these needs, which are also consistent with GA4GH29 metadata 
model systems.
Page 9 of 14
F1000Research 2017, 6:1488 Last updated: 14 NOV 2017
evaluate the reusability (R) of the data. The latter will be enhanced 
if our recommendation can push the regulation of the community 
standard in human data management. Thus, we suggest that by 
determining a few well-defined entities in a rigorous way, we 
can link existing initiatives, built with different purposes in mind, 
without the need for aligning their full data structures.
Ongoing implementation of a FAIRpoint system for EGA
EGA has traditionally only allowed a limited set of data to be 
available publicly because of its controlled-access database. These 
would be the study, DAC, and dataset objects. This study has shown 
that for EGA to become fully FAIR, EGA needs to allow all other 
objects with PIDs to be publicly queryable. EGA can ensure secu-
rity by restricting the attributes of the PIDs that are visible pub-
licly, but allow the PID itself to be public. For example, as each 
file in EGA has a PID, this PID could be public, while the filename 
could be under controlled access, allowing the full structure and 
links between objects at EGA to be accessible. EGA is developing 
a new API that will allow the relationships between all objects to be 
determined (linked data) while ensuring controlled access data is 
not public. Example queries would be: 
•    ’List all files from sample A’
•    ’List all samples used in file B’
•    ’List all files of type C in study D’
•    ’List all samples in dataset E’
•    ’Return the experiments that were performed on sample F 
by study G’
Additionally, filters can be applied to restrict results by attributes 
associated with an object, such as ’Return all BAM files from male 
samples in study H’. EGA should also extend the extant relevant 
digital objects listed at identifiers.org30 for each of which EGA is 
responsible for generating a PID, ensuring that each of these objects 
will have a unique uniform resource identifier (URI).
Conclusions
Our implementation study advances the role of EGA from a 
data archive towards a data port, where data can more readily be 
reused; additionally, our implementation study has made it pos-
sible to link tranSMART, Galaxy and EGA into a full data reuse 
ecosystem. Interoperability is the centrepiece among all the 
challenges in linking data and our recommendation offers one 
solution to it. In addition, this implementation study allowed us 
to make several recommendations for future projects to improve 
FAIRness of the designed ecosystem.
Methods
Data model mapping
We map the data model of tranSMART (v16.1) and that of EGA. 
In Figure 2, “study” in both databases are mapped; “interpreted 
data” is mapped to “analysis” or “run” in EGA which corresponds 
to one or multiple EGA file IDs (see the section “Data and software 
availability”).
TraIT-CLUC data
TraIT-CLUC data are used in this implementation study for test 
purposes because they do not have privacy issues. TraIT-CLUC 
data include results obtained from various high-throughput molec-
ular profiling techniques, such as microarrays, next generation 
sequencing and tandem mass spectrometry. Raw data were 
restructured to be uploaded into EGA; the interpreted data were 
rendered as the tranSMART-ready format to be uploaded into 
tranSMART (see Data and software availability).
Data uploading and publishing
Data upload into EGA. Raw TraIT-CLUC data including FASTQ 
and BAM files were uploaded into EGA together with their 
metadata.
Data files were transferred to EGA archival via FTP after being 
encrypted locally. Metadata were filled into XML files and uploaded 
into EGA via its API. The raw TraIT-CLUC data have been 
structurally published in EGA.
Data upload into tranSMART. The interpreted TraIT-CLUC 
tranSMART-ready data were uploaded into tranSMART using 
transmart-batch32.
EGA data into Galaxy
A Galaxy tool called ega_download_streamer26 was used, which 
wraps EGA download client into Galaxy. We set up an EGA 
account with access to TraIT-CLUC data into Galaxy. By providing 
an EGA file identifier, this tool enables the automatic download 
of data from EGA into Galaxy.
Data and software availability
TraIT-CLUC data
The raw TraIT-CLUC data structurally published in EGA can be 
accessed via EGA Study ID EGAS00001001476. These data are 
public and therefore anyone can request the access to the datasets 
under EGA Study ID EGAS00001001476 via EGA help desk (DAC 
ID: EGAC00001000514). The access to the tranSMART-ready 
TraIT-CLUC interpreted data can be found at https://trng-b2share.
eudat.eu/records/21bdc3128e1541da83dc48c51cd39a5f. How to 
load the tranSMART-ready data into tranSMART can be found at 
http://cluc.trait-platform.org.
tranSMART
tranSMART (v16.1) is used in this implementation study. 
Information about a demo server of tranSMART showcasing 
the data model mapping of this work can be found at http://cluc. 
trait-platform.org.
Galaxy
A Galaxy instance can be deployed either from the source code 
or from a Docker image. More information can be found at 
https://galaxyproject.org/. Galaxy tool “EGA download streamer” 
can be installed from the main Galaxy tool shed under the name 
“ega_download_streamer” within the Galaxy instance. The source 
code can be found at http://dx.doi.org/10.5281/zenodo.16733033.
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This is a quite unusual paper.  It presents a demo with TraIT of a cell line use case (CLUC) to combine
functions, samples, and datasets  from tranSMART (v16.1) and EGA into workflows in Galaxy.  I was
pleased to see proteomics identified as a key data type in Figure 3.
 
Figure 4 shows the metadata mapping and the assessment of the FAIR principles.
 
The Discussion of the ELIXIR implementation lays out improvements needed.  Sometimes we might
require a manuscript to report the implemented improvements, with results, but in this complex situation,
including recommendations for managing public access versus controlled access across different
independent resources, I think indexing at this stage is worthy.  The model of ORCID IDs for researchers
and their publication DOI's is a useful analogy.
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This paper describes the work implemented in the context of an ELIXIR implementation study, which aims
at building a proof of concept for an infrastructure that links reference omics data (from the EGA) with a
workflow environment (Galaxy) and a data integration platform hosting interpreted data (transMART).
The authors make a clear case of showing the interest of their approach, which is to facilitate the
discovery and reusability (overall, the FAIRness) of clinical data. A prototype “ecosystem” has been built
to evaluate this approach. As the authors mention, this paper builds, among other things, on the work
presented in “Integration of EGA secure data access into Galaxy” , which had also introduced the project.
The results of this work are quite encouraging, as the implementation study demonstrates that despite
technical issues such as the difference of the data model for different components (EGA and transMART),
their integration remains possible.
The last “Recommendations” section is helpful in understanding the limitations of the current work. Of
particular importance in my opinion is recommendation 5 to move to a “mature solution”, which explains
the difference of implementation between the initial analysis and the re-analysis workflows by the
restriction of Galaxy usage to smaller scales than the “production workflows” used initially. This raises the
question of workflow portability between and Galaxy and other workflow management systems. I
personally think that CWL   (an initiative I am currently part of) could be used as a standard language to
define workflows which can be run both in high-throughput production environments, and in graphical
workbench systems like Galaxy. From a more general perspective, most of the recommendations
corresponding to potential modifications in the “partner systems” (EGA, Galaxy, transMART), it would be
interesting to know if they have been communicated to the corresponding communities, and to be able to
track the evolution of these requests.
A last minor point is that I would modify figure 3 to transform the “Export raw” between EGA and Galaxy
into an “Import raw data”, as the data transfer is controlled from Galaxy rather than from EGA.
References
1. Hoogstrate Y, Zhang C, Senf A, Bijlard J, Hiltemann S, van Enckevort D, Repo S, Heringa J, Jenster G,
J A Fijneman R, Boiten JW, A Meijer G, Stubbs A, Rambla J, Spalding D, Abeln S: Integration of EGA
secure data access into Galaxy. . 2016;  .   |   F1000Res 5 PubMed Abstract Publisher Full Text
2. O'Connor BD, Yuen D, Chung V, Duncan AG, Liu XK, Patricia J, Paten B, Stein L, Ferretti V: The
Dockstore: enabling modular, community-focused sharing of Docker-based genomics tools and
workflows. . 2017;  : 52   |   F1000Res 6 PubMed Abstract Publisher Full Text
Is the rationale for developing the new method (or application) clearly explained?
Yes
Is the description of the method technically sound?
1
2
Page 13 of 14
F1000Research 2017, 6:1488 Last updated: 14 NOV 2017
 Is the description of the method technically sound?
Yes
Are sufficient details provided to allow replication of the method development and its use by
others?
Yes
If any results are presented, are all the source data underlying the results available to ensure full
reproducibility?
Yes
Are the conclusions about the method and its performance adequately supported by the
findings presented in the article?
Yes
 No competing interests were disclosed.Competing Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
The benefits of publishing with F1000Research:
Your article is published within days, with no editorial bias
You can publish traditional articles, null/negative results, case reports, data notes and more
The peer review process is transparent and collaborative
Your article is indexed in PubMed after passing peer review
Dedicated customer support at every stage
For pre-submission enquiries, contact   research@f1000.com
Page 14 of 14
F1000Research 2017, 6:1488 Last updated: 14 NOV 2017
